Lipum AB (publ) (LIPUM.ST)
Lipum AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Umeå, SE. The stock last traded at $14.35, up 0.70% on the session, giving a market capitalisation of $304.4M. Its beta of 0.26 implies it has historically moved less than the broad market.
Lipum AB (publ) is a biopharmaceutical firm based in Sweden, focused on pioneering the discovery and development of therapeutic solutions for long-term inflammatory conditions. The company's primary therapeutic asset, SOL-116, is a humanized antibody currently in the late preclinical stage, designed to treat pediatric rheumatism and adult rheumatoid arthritis. To facilitate the advancement of SOL-116 into clinical trials, Lipum has established a collaboration with Pelago Bioscience AB to meticulously monitor drug targets. Founded in 2010, the company's operations are headquartered in Umeå, Sweden.
Lipum AB (publ) is most often compared with the following Healthcare names: